Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735 Cambridge Epigenetix names Peter Fromen as Chief Executive Officer Phase Four and Impulse Space to collaborate on multi-mode propulsion Vascular Therapies completes $25 million private financing Introducing Avari Wireless, a state-of-the-art designer & manufacturer of public safety DAS Paragraf raises $60 million in Series B financing